|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00143130 |
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.
Condition | Intervention | Phase |
Seizures |
Drug: Pregabalin |
Phase III |
Genetics Home Reference related topics: | pyridoxal 5'-phosphate-dependent epilepsy |
MedlinePlus related topics: | Seizures |
ChemIDplus related topics: | Pregabalin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-Month Follow-on Open-Label, International, Multicenter Add-on Therapy Trial |
Enrollment: | 227 |
Study Start Date: | April 2005 |
Study Completion Date: | September 2007 |
Arms | Assigned Interventions |
Single Arm: Experimental |
Drug: Pregabalin
Pregabalin
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 47 Study Locations |
Pfizer |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
To obtain contact information for a study center near you, click here. 
  |
Link to ClinicalStudyResults.org Posting 
  |
Responsible Party: | Pfizer, Inc. ( Clinical Trials Disclosure Group ) |
Study ID Numbers: | A0081015 |
First Received: | August 31, 2005 |
Last Updated: | September 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00143130 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|